All News
LLDAS: Predicting Pregnancy Outcomes
Pregnancy in SLE is a high risk situation and active disease can lead to fetal loss, pre-term birth, IUGR and neonatal lupus syndromes. In a study by Dr. Michelle Petri and colleagues, they evaluated whether the LLDAS at the start of pregnancy was predictive of pregnancy outcome.
Read Article
Following the results of the FAST trial, would you have any concerns about prescribing febuxostat if clinically indicated?
#ACR20 @RheumNow
David Liew drdavidliew ( View Tweet)
Just as a reminder of how we felt back then.
https://t.co/onIMqa5DAp
Also note, the hypogammaglob gap has widened a little (then 25 v 21, now 36 v 26).
Now we have the extended follow-up data, where no additional benefit was noted, do we still feel that excited? #ACR20 @RheumNow
David Liew drdavidliew ( View Tweet)
Improvement of enthesitis US scores consistent with bDMARD initiation/change
1⃣MASEI and OMERACT scores improved at 3 mo/6mo
2⃣Associated with clinical activity outcomes
@RheumNow #ACR20 Abs#1552 https://t.co/qnSEBaXrJo
Robert B Chao, MD doctorRBC ( View Tweet)
RITZAREM
(RTX vs AZA maintenance post RTX induction relapsing AAV)
what happened post-study?
After #ACR19, hope RTX confers ongoing benefit
Answer: no. Same decline
Is 1g q4m dosing not justified?
Does that mean RTX needs to be continued, and in whom?
#ACR20 ABST2052 @RheumNow https://t.co/tldGqca8xC
David Liew drdavidliew ( View Tweet)
Did you have diversity and inclusion and/or bias training during fellowship? #ACR20 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
GOUT: CARES study says febuxostat has high CV risk, new FAST study says no incr risk. Would you give FEB to a gout pt w/ CV risk?
Dr. John Cush RheumNow ( View Tweet)
When diagnosing Febrile, possible autoinflammatory, Stills disorders do you order genetic testing
Dr. John Cush RheumNow ( View Tweet)
Rheum Now shares Day 3 highlights from #ACR20.
https://t.co/xNv1fG97ib https://t.co/Psa8bRqlVh
Links:
Dr. John Cush RheumNow ( View Tweet)
Congratulations to House of DMARDs, our new @ACRheum 2020 Knowledge Bowl Champions!! 🏆 We are so proud!! @kmdsilvaMD @JonathanDauMD @NasrallahMazen #ACR20 https://t.co/iFaMRNB5D3
MGH Rheumatology MGHrheumatology ( View Tweet)
Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20
Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. 31/33 patients continue in OLE https://t.co/kVQWN1s8Zy
The Lancet Rheumatology TheLancetRheum ( View Tweet)
These kind of studies must be done, but this result is to nobody’s surprise! #PedsRheum
Let’s keep working together to move the bar towards recognition that #sJIA and #AOSD are a single condition that can affect people of all ages! https://t.co/qzbgeKPlqw
Michael Ombrello MichaelOmbrello ( View Tweet)
Gout has more comorbidities than RA & PsA #1466 Half of respondents are correct @RheumNow @CRASCRRheum #ACR20 https://t.co/hjwYvCFJPk
Janet Pope Janetbirdope ( View Tweet)
Join now. Free to #ACR20 attendees. Women leaders in rheumatology @RheumNow @CRASCRRheum https://t.co/nIqZ8qTINY
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Awesome succinct guidelines!#acrbest #acr20 @RheumNow https://t.co/lzLykOY8G0
alexa meara lexmeara ( View Tweet)
VEXAS! Hot topic of the year #ACR2020 ABS#1953 @RheumNow https://t.co/RIQKsoWbHe
Bella Mehta bella_mehta ( View Tweet)
Mavrilimumab (anti GM-CSF receptor α Mab) efficacious in maintaining disease remission in GCA pts.
Phase 2 trial (n=70)
1⃣Disease flare 19% in tx vs. 46% in PBO at 26wk
2⃣Sustained remission 83% vs. 50% in PBO
3⃣Similar AE in both groups
@RheumNow #ACR20 Abs#L06 https://t.co/LqiNKJffFo
Robert B Chao, MD doctorRBC ( View Tweet)
@RheumNow #ACR20 Abs L08 Prospective 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat was not associated w/increased risk of death compared w/allopurinol. 222 (7·2%) pts died in the febuxostat group compared to 263 (8·6%) in the allopurinol group
Olga Petryna DrPetryna ( View Tweet)
#ACR20 @RheumNow https://t.co/ImXVcDIl4V
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
